Veno-Arterial Extracorporeal Membrane Oxygenation Rescue in a Patient With Pulmonary Hypertension Presenting for ...
Echocardiographic Grading System Could Better Risk Stratify People With PAH
A new report aims to create consistency out of a number of observations about associations between echocardiographic values by analyzing them in the context of real-world patient outcomes.
New research suggests that mapping out the relationships between right heart function values can help clinicians better risk-stratify patients with pulmonary arterial hypertension (PAH).
The report aims to create consistency out of a number of observations about associations between echocardiographic values by analyzing them in the context of real-world patient outcomes.
Corresponding author Bettia E. Celestin, PhD, of Stanford University, and colleagues, said a number of biomarkers for right heart failure (RHF) have been identified in the past three decades. They noted that RHF is the most important cause of mortality in PAH. Those biomarkers include triscuspid annular plane systolic excursion (TAPSE), right ventricular (RV) free wall longitudinal strain, right ventricular end systolic dimension, and right atrial (RA) size and function.
"With the multiplicity of right heart parameters, ensuring consistency in grading systems becomes even more important," Celestin and colleagues said, writing in the journal Pulmonary Circulation.
The team advises that one way to ensure consistency is to leverage the relationships between different right heart parameters.
They noted, among other relationships, that a 2020 study found links between RV free wall longitudinal strain and right ventricular ejection fraction in patients with pulmonary hypertension.
"These physiological relationships can help ensure consistency between thresholds for risk stratification," they said. "In addition, they can help guide consistency between grading systems in PAH."
Celestin and colleagues set out to evaluate those relationships by comparing them to patient outcomes. They constructed a cohort of patients with Group 1 PAH who underwent right heart catheterization and echocardiography within 2 weeks of each other at Stanford Hospital. The patients were all adults, and their diagnoses came between 2002 and 2021.
The authors evaluated a number of echocardiographic variables, and then tracked patients to see which patients experienced death or lung transplant over the course of 5 years.
Of the 223 patients who met inclusion criteria, 78% were female, and the group had an average age of 48.1 years. The patients had a mean pulmonary arterial pressure of 51.6 (13.8) mmHg and pulmonary vascular resistance index of 22.5(6.3) WU/m2, the authors found.
As with previous studies, the authors found correlations between right heart parameters. Specifically, they found RV free wall longitudinal strain and RV fractional area change were closely linked, though they found TAPSE and RV free wall longitudinal strain had a weaker relationship.
At 5 years, 35% of patients had experienced either death or a lung transplant. The authors then used those outcomes to create an echocardiographic grading system for PAH, and then used those thresholds to assess the Registry to Evaluate Early and Long-Term PAH Disease Management echocardiographic risk score (REVEAL-ECHO), which was published last year.
In the latter analysis, they found REVEAL-ECHO scores were associated with survival in their validation cohort. The authors also found that REVEAL Lite scores correlated with patient outcomes. Those with a score of at least 8 had a 20% risk of death or transplantation at 1 year, and a 50% risk at 5 years.
The investigators said the mathematical relationships they identified between right heart parameters have implications for clinical practice. For example, they said if a patient is found to have highly discordant RV fractional area change and RV free wall longitudinal strain values, further investigation is warranted to make sure the readings are accurate.
"In addition, the strong association between many variables will likely simplify the number of features needed for phenomapping and profiling," they wrote. "Finally, these mathematical relationships may further verify consistency in grading between metrics."
The investigators said there are limitations to their study, including factors related to its single-center setting. For instance, they said their measures were performed in a laboratory dedicated to right heart measures, and thus may not be reflective of usual clinical practice.
Heart Failure, Pulmonary Hypertension And Cardiology ICU Fellowship Program
In our comprehensive one-year Heart Failure Fellowship program, you will gain robust comprehensive inpatient and outpatient training in the specialty of heart failure.
Our one-year fellowship is offered to PGY-4 level candidates for training focused on heart failure management, pulmonary HTN, with cardiology ICU exposure. Fellows develop the ability to recognize and manage heart failure and understand disease progression. This is a non-standard training (NST) program that is not ACGME accredited.
Our program provides superior cardiology training in a collaborative environment. We have specialty clinics across our medical campus, which is anchored by our 1,200 bed inpatient center UAB Hospital—the eighth largest public hospital in the nation. The hospital is in close proximity to the Birmingham VA Medical Center, UAB Hospital Highlands campus, The Kirklin Clinic, and Children's Hospital of Alabama where fellows also train.
Clinical RotationsOur program offers comprehensive, multidisciplinary training within a collaborative environment. We focus on developing our heart failure fellows by expanding their expertise in areas of advanced heart failure, transplant cardiology, mechanical circulatory support, and pulmonary vascular disease through a combination of inpatient and outpatient care. At the Kirklin Clinic, fellows will engage in specialized clinics for CHF, PH, VAD, transplant, and biopsy suites.
At the Birmingham VA Medical Center, fellows manage a panel of patients longitudinally throughout their training. They also participate in Block model rotations, covering general cardiology, arrhythmia, heart failure, pulmonary hypertension, and elective time including adult congenital heart disease over the three-year program.
Our inpatient services are anchored in our heart transplant ICU, where leading-edge clinical programs for heart transplant, VAD, and PH are managed. Our teams work closely with cardiovascular surgery and interventional/structural cardiologist to address cardiogenic shock using temporary MCS techniques like ECMO, Impella, and TandemHeart. Furthermore, we provide exposure to unique clinical programs such as Cardio-Obstetrics, Cardio-Oncology, and Amyloid/infiltrative cardiomyopathies. Our heart failure fellows aid in supporting our team in managing complex valvular diseases.
Research OpportunitiesOur Heart Failure, Pulmonary Hypertension and Cardiology ICU program works closely with the UAB Comprehensive Cardiovascular Center to foster multi-disciplinary and multi-investigator collaborations and programmatic development in cardiovascular research. We strive to enrich our fellows training experience by exposing them to cutting-edge research in basic, clinical, population, and translational cardiovascular research.
It's not just what you learn. It's also about the people you learn with. Our cardiology fellowship program leaders are dedicated to developing the potential of every talented trainee.Meet our people
Frequently Asked QuestionsAll applications are reviewed by our UAB Cardiology Review Team. All submissions require the following documents:
Current CV (updated within 3 months)
Medical School Transcripts (and diploma if requested)
Letter from Interventional Cardiology Program Director
Three (3) total Letters of Recommendation
Certificate/verification from previous residency training
Must be eligible for Alabama Medical License and Alabama Controlled Substance Certificate (all step scores completed at the time of application)
Must be eligible for Federal DEA registration
Valid ECFMG Certificate (IMG only)
There is no minimum USMLE score requirement. We take the score into account as part of the overall review of an application.
Applications Open and Close — Applications open Decemeber 1 and close December 31.
Applications Reviewed — December
Interview Invitations Released — Mid December
Interviews Begin — December
Fellowship begins — July 1
It would be my pleasure to speak with you about the amazing training opportunties we provide at UAB. Please contact me if you have any questions about our Heart Failure, Pulmonary Hypertension and Cardiology ICU Fellowship program. Andrew Lenneman, M.D., Program Director
Send an Email
I'd be delighted to talk with you about the many exciting possibilities that await you at UAB and Birmingham. Contact me for more details about our fellowship.
Joanna Joly, M.D., Associate Program Director
Send an Email
Study Indicates Mortality In Rheumatic Heart Disease Is High
Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June 5 in the Journal of the American Medical Association.
Ganesan Karthikeyan, D.M., from the All India Institute of Medical Sciences in New Delhi, and colleagues assessed the risk and predictors of major patient-important clinical outcomes in patients with clinical RHD. Analysis included 13,696 patients in 24 low- and middle-income countries.
The researchers found that over a median duration of 3.2 years, 15% of patients died overall (4.7% per patient-year). Vascular causes accounted for most deaths (67.5%), mainly heart failure or sudden cardiac death. Both stroke (0.6% per year) and recurrent rheumatic fever was rare.
Higher mortality was seen with markers of severe valve disease, including congestive heart failure (hazard ratio [HR], 1.58), pulmonary hypertension (HR, 1.52), and atrial fibrillation (HR, 1.30). Lower mortality was seen with surgical treatment (HR, 0.23) or valvuloplasty (HR, 0.24). Lower mortality was also seen with higher country income level, when adjusting for patient-level factors.
"Study findings suggest a greater need to improve access to surgical and interventional care, in addition to the current approaches focused on antibiotic prophylaxis and anticoagulation," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Bayer, which funded the study.
More information: Ganesan Karthikeyan et al, Mortality and Morbidity in Adults With Rheumatic Heart Disease, JAMA (2024). DOI: 10.1001/jama.2024.8258
© 2024 HealthDay. All rights reserved.
Citation: Study indicates mortality in rheumatic heart disease is high (2024, June 7) retrieved 10 June 2024 from https://medicalxpress.Com/news/2024-06-mortality-rheumatic-heart-disease-high.Html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Comments
Post a Comment